U.K. Bioindustry Plots Its Post-Brexit Course
Improving Manufacturing of Advanced Therapies Is One of Several Initiatives Being Put in Place
GEN Roundup: Kinase Assays from Preliminary Screens to “Smart” Deployment
GEN Interviewed Six Experts to Explore Kinase Assays
When the Pressure Is High the Dementia Is Low
Sounds of Science Podcast
Tuning Up or Taming Immune Responses
New Immunotherapeutic Strategies Include Bispecific Antibodies, Engineered Adenoviruses, and Specifically Formulated Vaccines against Cancer
GEN Reports on Global Bioclusters Vying for Life Science Dominance
New Rochelle, NY, June 5, 2012— “The U.S. remains the world’s major superpower but its dominance in biopharma is slipping,” reports Genetic Engineering & Biotechnology News (GEN). China and India are the main challengers as they add innovative capabilities to their rapidly expanding biotechnology industries, according to the most recent issue of GEN.
“Both China and India have targeted bioscience as a key economic sector for the 21st century,” said John Sterling, Editor-in-Chief of GEN. “They are providing strong political and financial support to create dominant bioindustries.”
The GEN article specifically compares the current status of biotech in China and India to that of two significant U.S. regions, California and Massachusetts, two states that have long served as anchors for the country’s biotechnology efforts. Biotechnology in India and China is growing faster than in the U.S. and other countries. Both Eastern nations emerged more than a decade ago as offshoring havens driven by lower wages and less red tape.
India has capitalized on strong chemistry, generic drug development, and working as a service sector. China invested heavily in biopharma infrastructure and its drug market zoomed from $33 billion in 2007 to $126 billion in the first seven months of 2011.
The China/India article also features GEN’s picks for the top 15 U.S. biotech clusters and the top 10 Non-U.S. bioclusters.
Supplementing the China/India analysis are articles on U.K. Biopharma Bouncing Back, Emerging Markets Turning to Innovation, and Intellectual Property Considerations for Firms Doing Business in China and India.